Format

Send to

Choose Destination
Am J Ther. 2017 Mar/Apr;24(2):e207-e212. doi: 10.1097/MJT.0000000000000390.

A Topical Medication of All-Trans Retinoic Acid Reduces Sebum Excretion Rate in Patients With Forehead Acne.

Author information

1
1Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Beijing, China; 2Department of Bone Tissue Engineering Lab, Beijing Traumatology and Orthopedics Research Institute, Beijing Jishuitan Hospital, Beijing, China; and 3Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.

Abstract

Acne is a disease of the hair follicles of the face, chest, and back that affects almost all teenagers during puberty. This study is conducted to investigate if all-trans retinoic acid (ATRA) could reduce sebum excretion rate (SER) in acne patients by influencing content of skin-surface lipid production. Thirty-nine patients with forehead acne were topically treated with cream base (vehicle) and 0.025% ATRA cream once a night for 7 days. Separation and identification of sebum production collected from the skin on the acne were performed using thin-layer chromatography. SER was calculated according to the total amount of individual sebum productions that were quantified by using Alphaimager IS-2200 imaging analysis. Our data showed that the value of SER on the acne-affected skin was significantly decreased in the ATRA-treated patients as compared with ones treated with vehicle (P < 0.01). Treatment with ATRA resulted in inducing significant decreases in the contents of wax esters (WE), triglycerides and fatty acids, and free fatty acids (FFA) productions (all P < 0.01). In further analysis, the changes in the data before and after treatments with vehicle and ATRA were compared with significant differences exhibited in the values of SER, WE, and FFA (all P < 0.05). This study indicates that the topical application of ATRA in treatment of acne patients induces decrease in SER by inhibiting the excretion of WE and FFA productions.

PMID:
26872139
DOI:
10.1097/MJT.0000000000000390
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center